Form 4: UNH Optum CEO Reports Scheduled Equity Transactions

UnitedHealth Group's Optum CEO, Patrick H. Conway, reported scheduled acquisitions of restricted stock units and non-qualified stock options, alongside a disposition for tax purposes.

Summary

• Patrick H. Conway, Chief Executive Officer of Optum, reported transactions involving UnitedHealth Group (UNH) common stock and derivative securities.
• On February 23, 2026, Conway disposed of 178.988 shares of common stock at $282.34 per share, which is typically for tax withholding purposes related to equity vesting.
• Conway acquired 8,855 shares of common stock at $0, representing the vesting of restricted stock units. These RSUs are scheduled to vest at a rate of 25% annually on February 23 from 2027 through 2030.
• Conway also acquired 35,517 non-qualified stock options at $0, with an exercise price of $282.34. These options are scheduled to vest at a rate of 25% annually on February 23 from 2027 through 2030, and will expire on February 23, 2036.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-arranged.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting ongoing executive incentive alignment and retention through significant equity grants, which is a standard and healthy corporate governance practice.

Positives

• Grant of 8,855 restricted stock units (RSUs) at a price of $0, indicating equity compensation designed to align executive interests with long-term shareholder value.
• Grant of 35,517 non-qualified stock options at a price of $0, providing future upside potential if the stock price exceeds the exercise price of $282.34.
• Transactions are part of a Rule 10b5-1(c) plan, which demonstrates pre-planned equity management and reduces concerns about opportunistic insider trading.

Negatives

• Disposition of 178.988 shares of common stock, although likely for tax purposes related to equity vesting, results in a reduction of direct share ownership.

Future Outlook

The filing details future vesting schedules for restricted stock units and non-qualified stock options, indicating a long-term incentive structure for the executive through February 2030.

Industry Context

StockSavvy.ai notes that equity compensation, including restricted stock units and stock options, is a standard practice in the healthcare and insurance industry for retaining and incentivizing senior executives like Optum's CEO. The use of a 10b5-1 plan is also common for executives to manage their equity holdings in a compliant manner.

Comparison to Industry Standards

• The grant of RSUs and stock options with multi-year vesting schedules is consistent with executive compensation practices at large-cap healthcare companies such as CVS Health (CVS), Elevance Health (ELV), and Cigna Group (CI), which typically use similar long-term incentive structures to align executive interests with shareholder value over several years.
• The exercise price of the non-qualified stock options ($282.34) being equal to the disposition price of common stock suggests it aligns with the market price on the grant date, a common practice for at-the-money option grants.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the executive's long-term interests with shareholder value creation. The disposition for tax purposes is a routine event and has minimal impact.
• Employees: No direct impact on general employees is indicated.

Next Steps

• Annual vesting of restricted stock units (25% annually) on February 23 from 2027 through 2030.
• Annual vesting of non-qualified stock options (25% annually) on February 23 from 2027 through 2030.
• Expiration of non-qualified stock options on February 23, 2036.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants and a related tax withholding transaction for an executive. While the grants are positive for executive retention and alignment, they are standard practice and do not present new information that would significantly alter the investment thesis for UnitedHealth Group. Therefore, a "hold" recommendation is appropriate as this filing does not provide a strong catalyst for a buy or sell decision.

Keywords

UnitedHealth Group, UNH, Optum, Patrick Conway, SEC Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Stock Options, 10b5-1 Plan